ClinicalTrials.gg

Program

Potassium Chloride

Also written as “Custodiol”, “HalfLytely” and “PLENVU®”.

Its studies are mostly in Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 3 companies.

Furthest: phase 4, since Feb 14, 20148 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. F. Köhler Chemie41 open or runningphase 3since Feb 14, 2014Sep 29, 2011Jan 2027phase 2 · NCT06032195
Sebela Pharmaceuticals30 open or runningphase 4since Sep 9, 2005Sep 9, 2005none ahead
Norgine11 open or runningphase 3since Oct 16, 2025Oct 16, 2025Jan 6, 2027phase 3 · NCT07218523

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2005First study: phase 4 study in ColonoscopyNew to Sebela PharmaceuticalsSebela Pharmaceuticals · NCT00164177 · 20 enrolled · United States
  2. Sep 9, 20052 phase 3 studies in ColonoscopySebela Pharmaceuticals · NCT00164164, NCT00164151
  3. Sep 29, 2011Dr. F. Köhler Chemie's first study: phase 2 study in Coronary Artery DiseaseNew to Dr. F. Köhler ChemieDr. F. Köhler Chemie · NCT01444235 · 102 enrolled · Germany
  4. Feb 14, 2014Phase 3 study in Aortic Valve DiseaseDr. F. Köhler Chemie · NCT02098772 · 530 enrolled · Germany
  5. Aug 11, 2015Phase 3 study in Heart FailureDr. F. Köhler Chemie · NCT02869022 · 105 enrolled · Austria, Germany
  6. Aug 21, 2023Phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195 · 15 planned · Germany
  7. Oct 16, 2025Norgine's first study: phase 3 study in Bowel Cleansing Prior to Clinical ProceduresNew to NorgineNorgine · NCT07218523 · 212 planned · Belgium, Croatia, Germany and more

Ahead

  1. Jan 2027Primary completion: phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195
  2. Jan 6, 2027Primary completion: phase 3 study in Bowel Cleansing Prior to Clinical ProceduresNorgine · NCT07218523

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07218523Bowel Cleansing Prior to Clinical Procedures · Belgium, Croatia, Germany and more3RecruitingNorgineJan 6, 2027212
NCT06032195Heart Transplantation · Germany2RecruitingDr. F. Köhler ChemieJan 202715
NCT02869022Heart Failure · Austria, Germany3CompletedDr. F. Köhler ChemieSep 2, 2019105
NCT02098772Aortic Valve Disease · Germany3CompletedDr. F. Köhler ChemieNov 16, 2018530
NCT01444235Coronary Artery Disease · Germany2CompletedDr. F. Köhler ChemieMay 2012102
NCT00164177Colonoscopy · United States4CompletedSebela PharmaceuticalsDec 200420
NCT00164164Colonoscopy · United States3CompletedSebela PharmaceuticalsJun 2000200
NCT00164151Colonoscopy · United States3CompletedSebela PharmaceuticalsMay 200260

How it is read

Names in the registry

  • “Custodiol”, 4 entries
  • “HalfLytely”, 3 entries
  • “PLENVU®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.